Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA® and ISTODAX®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs® compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe our commercial stage products and the depth of our product pipeline, provide the catalysts for future growth.
Jun 22, 2017
Celebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgene's SHOW MORE OF YOU Campaign
Jun 19, 2017
May 31, 2017 at 4:00 PM ET
May 23, 2017 at 1:30 PM ET